Sol-Gel Technologies Ltd.'s SEC filings document the disclosure record of a foreign private issuer developing and partnering dermatology drug products. Form 6-K reports include operating and financial results, unaudited condensed financial statements, clinical and regulatory updates for SGT-610, SGT-210 and EPSOLAY, and material-event disclosures incorporated by reference into the company's Form S-8 and Form F-3 registration statements.
The filings also cover shareholder meeting materials, auditor appointments, board elections, interim executive leadership approvals under Israeli corporate governance requirements, and capital-structure matters involving the company's ordinary shares. These documents frame Sol-Gel's public-company reporting around dermatology pipeline development, approved topical products, licensing arrangements, governance actions, and financing capacity.
Opaleye Management Inc., a more than ten percent owner of Sol-Gel Technologies Ltd., reported an indirect open-market purchase of 951 Ordinary Shares on 2026-08-12 at $71.50 per share, held via Opaleye, L.P. Following this trade, that fund’s indirect holdings in Sol-Gel total 494,887 Ordinary Shares. A separate line reports 15,000 Ordinary Shares held in a managed account. Opaleye Management Inc. states that it may be deemed to beneficially own these securities through its roles with the fund and managed account, but disclaims beneficial ownership except to the extent of its pecuniary interest.
Opaleye Management Inc., a ten percent owner of Sol-Gel Technologies Ltd., reported net insider buying. Through Opaleye, L.P., it purchased 775 ordinary shares on July 13 and 920 shares on July 14, 2026, in open‑market transactions at weighted‑average prices of $73.89 and $73.43 per share, executed in multiple trades within disclosed ranges of $73.34–$73.50 and $73.75–$73.95. Following these trades, Opaleye, L.P. holds 493,936 shares, and a separately managed account overseen by Opaleye Management holds 15,000 shares. Opaleye Management disclaims beneficial ownership beyond its pecuniary interest.
Opaleye Management Inc., a more than ten percent owner of Sol-Gel Technologies Ltd., reported open-market purchases of the company’s ordinary shares. On July 8, 2026, an affiliated fund bought 300 shares at $73.69 per share, and on July 10, 2026 it bought an additional 229 shares at $73.95 per share. After these trades, the fund held 492,241 shares indirectly attributed to Opaleye Management Inc., and a separately managed account associated with it held 15,000 shares, with Opaleye Management Inc. disclaiming beneficial ownership beyond its pecuniary interest.
Opaleye Management Inc., a more than ten percent owner of Sol-Gel Technologies Ltd., reported additional indirect purchases of the company’s ordinary shares. Through Opaleye, L.P., it completed open-market purchases totaling 1,712 shares at prices ranging from $71.96 to $71.99 per share. After these trades, Opaleye, L.P. held 491,712 ordinary shares, while a separately managed account overseen by Opaleye Management held 15,000 shares, both positions being reported as indirect holdings. Opaleye Management disclaims beneficial ownership of these shares beyond any pecuniary interest.
Sol‑Gel Technologies Ltd. Schedule 13G/A amendment shows Phoenix Financial Ltd. and its subsidiaries beneficially own 161,825.70 ordinary shares, equal to 4.99% of the outstanding ordinary shares.
The filing states the 4.99% stake is based on 3,245,270.00 ordinary shares outstanding as of June 7, 2026 (source: Bloomberg LP). Phoenix describes the shares as held through a partnership whose ownership allocations change under the partnership agreement.
Sol-Gel Technologies reported first quarter 2026 revenue of $0.1 million, down from $1.0 million a year earlier, mainly because 2025 included a milestone payment from Searchlight. Research and development expenses fell sharply to $2.8 million from $8.8 million, reflecting lower manufacturing and clinical costs.
Net loss narrowed to $3.7 million, or $1.31 per share, compared with a $8.8 million loss, or $3.2 per share, in 2025. As of March 31, 2026, Sol-Gel held $52.8 million in cash, deposits and marketable securities and expects this to fund operations into the first quarter of 2028.
Management highlighted a Notice of Allowance extending patidegib (SGT-610) exclusivity until 2044, support for a Phase 3 program in Gorlin syndrome with top-line results expected in the fourth quarter of 2026, and international partnerships for TWYNEO and EPSOLAY that may reach about $10 million in annual royalty revenue by 2031.
Sol-Gel Technologies Ltd. reported that entities managed by Opaleye Management Inc. made an open-market purchase of 1,563 ordinary shares on May 20, 2026 at a weighted average price of $64.4349 per share, with individual trades between $63.97 and $64.50. Following the transaction, an Opaleye-managed fund indirectly holds 490,000 shares, and a separately managed account holds 15,000 shares. Opaleye Management may be deemed to beneficially own these securities through its roles with the fund and managed account but disclaims beneficial ownership beyond its pecuniary interest.
Opaleye Management Inc., a ten percent owner of Sol-Gel Technologies Ltd., reported open-market purchases of the company’s ordinary shares through affiliated accounts. On May 12 and May 13, an affiliated fund, Opaleye, L.P., bought a total of 3,437 ordinary shares in two open-market transactions. The purchases were made at weighted average prices of $67.9833 and $66.8701 per share. After these trades, Opaleye, L.P. held 488,437 ordinary shares, while a separately managed account overseen by Opaleye Management held 15,000 ordinary shares. Opaleye Management disclaims beneficial ownership of these shares beyond its pecuniary interest.
Opaleye Management Inc., Opaleye, L.P. and James Silverman reported beneficial ownership of Ordinary Shares of Sol-Gel Technologies Ltd. The filing states the reporting persons collectively hold 500,000 shares, representing 15.41% of the class, based on 3,245,270 Ordinary Shares outstanding as of March 25, 2026. The Adviser and Fund relationship is disclosed: the Adviser advises the Fund and Mr. Silverman exercises control over the Adviser. The filing clarifies it should not be construed as an admission of beneficial ownership under Section 13.
Sol-Gel Technologies’ major shareholder Moshe Arkin filed Amendment No. 7 to Schedule 13D to update his ownership percentages after the company’s underwritten offering closed on March 25, 2026.
As of that date, Arkin Dermatology owned 1,806,856 Ordinary Shares, representing about 52.44% of Sol-Gel’s outstanding Ordinary Shares. Moshe Arkin directly owned 143,257 Ordinary Shares, or about 4.41% of the company. Through his control of Arkin Dermatology, he may be deemed to beneficially own a total of 1,950,112 Ordinary Shares, representing approximately 56.60% of Sol-Gel’s Ordinary Shares, based on 3,245,270 shares outstanding on March 25, 2026.